[
  {
    "ts": null,
    "headline": "Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences",
    "summary": "Health Hope Pharma Limited (\"HHP\") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. (\"Gilead\") for encequidar, a first-in-class P-glycoprotein (\"P-gp\") inhibitor in the field of virology.",
    "url": "https://finnhub.io/api/news?id=38c723c2ef9ea46e22be370fcb4e298437ded9adc2098e17cb07a44a5a6d2b57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759150080,
      "headline": "Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences",
      "id": 136915853,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Health Hope Pharma Limited (\"HHP\") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. (\"Gilead\") for encequidar, a first-in-class P-glycoprotein (\"P-gp\") inhibitor in the field of virology.",
      "url": "https://finnhub.io/api/news?id=38c723c2ef9ea46e22be370fcb4e298437ded9adc2098e17cb07a44a5a6d2b57"
    }
  },
  {
    "ts": null,
    "headline": "Cheapest S&P 500 Stocks Ranked: 30 Best Value Buys",
    "summary": "Discover 30 top large-cap stocks offering strong value and quality.",
    "url": "https://finnhub.io/api/news?id=128fd721f9f6e5596b2df433e7890d99c8fbaabc25a5e6304c77ff2d7740de20",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759141719,
      "headline": "Cheapest S&P 500 Stocks Ranked: 30 Best Value Buys",
      "id": 136915123,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189068007/image_2189068007.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Discover 30 top large-cap stocks offering strong value and quality.",
      "url": "https://finnhub.io/api/news?id=128fd721f9f6e5596b2df433e7890d99c8fbaabc25a5e6304c77ff2d7740de20"
    }
  },
  {
    "ts": null,
    "headline": "Hanmi's Oral Delivery Platform Compound Licensed to Gilead",
    "summary": "Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. (\"Gilead\") and Health Hope Pharma (\"HHP\") granting Gilead the exclusive rights to develop and commercialize encequidar.",
    "url": "https://finnhub.io/api/news?id=8669a6652d66f0fbe09ff978e43b4d1b6b635a192c3d1e770c123a2c0170f17e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759139100,
      "headline": "Hanmi's Oral Delivery Platform Compound Licensed to Gilead",
      "id": 136913719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. (\"Gilead\") and Health Hope Pharma (\"HHP\") granting Gilead the exclusive rights to develop and commercialize encequidar.",
      "url": "https://finnhub.io/api/news?id=8669a6652d66f0fbe09ff978e43b4d1b6b635a192c3d1e770c123a2c0170f17e"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Buy on Gilead Sciences (GILD)",
    "summary": "​Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 21, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $143. ​The analyst noted that the US CDC recently recommended the company’s Yeztugo for HIV […]",
    "url": "https://finnhub.io/api/news?id=830c6866a60d2e0c4415819348d69ae28075beee4a4ada75e2c4368a9c30a94b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759124378,
      "headline": "Morgan Stanley Maintains Buy on Gilead Sciences (GILD)",
      "id": 136913720,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "​Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 21, Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $143. ​The analyst noted that the US CDC recently recommended the company’s Yeztugo for HIV […]",
      "url": "https://finnhub.io/api/news?id=830c6866a60d2e0c4415819348d69ae28075beee4a4ada75e2c4368a9c30a94b"
    }
  },
  {
    "ts": null,
    "headline": "3 Unpopular Stocks We Approach with Caution",
    "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
    "url": "https://finnhub.io/api/news?id=5b27386261216fb31bd8ae085ad50ba4f5d9626059b7a85d35a8f4743a4a8530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759120478,
      "headline": "3 Unpopular Stocks We Approach with Caution",
      "id": 136913991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
      "url": "https://finnhub.io/api/news?id=5b27386261216fb31bd8ae085ad50ba4f5d9626059b7a85d35a8f4743a4a8530"
    }
  }
]